Drugs / AR-42
AR-42
Trials 6 · a red edge is where a trial was stopped
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR-42 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02569320 ↗ |
| Known as | (S)-HDAC 42 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191482 ↗ |
| Known as | NSC 731438 | “Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents.” PMID 26943915 ↗ Mar 2016 |
| Known as | Osu-hdac 42 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191482 ↗ |
| Known as | REC-2282 | “The Technology Commercialization Office has licensed AR-42 (now called REC‐2282) to Recursion Pharmaceuticals using the institution's standard terms, conditions, and approval...” PMID 34667843 ↗ Aug 20212“The Ohio State University (OSU) holds the patent on the investigational drug AR-42 (US 10/597,022). The Technology Commercialization Office has licensed AR-42 (now called...” PMID 33492438 ↗ Jan 2021 |
| Action | Inhibit | “AR-42 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.” NCT01129193 ↗ |
| Modality | Small molecule | “AR-42 is a small molecule” NCT02282917 ↗ |
| Route | Oral | “Patients receive oral AR-42 three times weekly on days 1-21.” NCT01129193 ↗ |